UNLABELLED: The (18)F-labeled aromatic amino acid 6-fluoro-3,4-dihydroxy-L-phenylalanine (6-(18)F-fluoro-L-DOPA) is widely used as a radiopharmaceutical in neurologic and oncologic PET. In this study, a novel approach to the preparation of carrier-added (CA) 6-(18)F-fluoro-L-DOPA in 3 radiosynthesis steps was developed and evaluated; in this approach, direct nucleophilic (18)F fluorination of a protected amino acid derivative was used. The method currently used for the routine preparation of 6-(18)F-fluoro-L-DOPA by electrophilic labeling is limited to the production of small amounts of activity at high costs. Alternative syntheses based on the advantage of large-scale production of nucleophilic (18)F-fluoride, however, either have resulted in insufficient enantiomeric purity or are difficult to automate because of the complexity of the necessary multiple steps. METHODS: An isotopic exchange reaction on the precursor (2S,5S)-tert-butyl-5-(4-benzyloxy-2-fluoro-5-formylbenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate was used. The formyl group served as the activating group in the (18)F-for-(19)F exchange with tetrabutylammonium bicarbonate for anion activation in N,N-dimethylformamide. The intermediate was converted to a hydroxy group by Baeyer-Villiger oxidation with meta-chloroperbenzoic acid. After final deprotection with hydrobromic acid, CA 6-(18)F-fluoro-L-DOPA was isolated by high-performance liquid chromatography. RESULTS: The precursor was obtained by an 11-step organic synthesis. The optimized isotopic (18)F exchange proceeded with a radiochemical yield of about 50%. The complete preparation and isolation of CA 6-(18)F-fluoro-L-DOPA thus far are possible with a radiochemical yield of about 22%, within a synthesis time of 105 min, and at a much higher specific activity than with the electrophilic method. The enantiomeric excess of the desired L-isomer was greater than 96%. CONCLUSION: The pathway to 6-(18)F-fluoro-L-DOPA by isotopic exchange not only is more efficient but also is suited to automation as a "one-pot" procedure.
UNLABELLED: The (18)F-labeled aromatic amino acid 6-fluoro-3,4-dihydroxy-L-phenylalanine (6-(18)F-fluoro-L-DOPA) is widely used as a radiopharmaceutical in neurologic and oncologic PET. In this study, a novel approach to the preparation of carrier-added (CA) 6-(18)F-fluoro-L-DOPA in 3 radiosynthesis steps was developed and evaluated; in this approach, direct nucleophilic (18)F fluorination of a protected amino acid derivative was used. The method currently used for the routine preparation of 6-(18)F-fluoro-L-DOPA by electrophilic labeling is limited to the production of small amounts of activity at high costs. Alternative syntheses based on the advantage of large-scale production of nucleophilic (18)F-fluoride, however, either have resulted in insufficient enantiomeric purity or are difficult to automate because of the complexity of the necessary multiple steps. METHODS: An isotopic exchange reaction on the precursor (2S,5S)-tert-butyl-5-(4-benzyloxy-2-fluoro-5-formylbenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate was used. The formyl group served as the activating group in the (18)F-for-(19)F exchange with tetrabutylammonium bicarbonate for anion activation in N,N-dimethylformamide. The intermediate was converted to a hydroxy group by Baeyer-Villiger oxidation with meta-chloroperbenzoic acid. After final deprotection with hydrobromic acid, CA 6-(18)F-fluoro-L-DOPA was isolated by high-performance liquid chromatography. RESULTS: The precursor was obtained by an 11-step organic synthesis. The optimized isotopic (18)F exchange proceeded with a radiochemical yield of about 50%. The complete preparation and isolation of CA 6-(18)F-fluoro-L-DOPA thus far are possible with a radiochemical yield of about 22%, within a synthesis time of 105 min, and at a much higher specific activity than with the electrophilic method. The enantiomeric excess of the desired L-isomer was greater than 96%. CONCLUSION: The pathway to 6-(18)F-fluoro-L-DOPA by isotopic exchange not only is more efficient but also is suited to automation as a "one-pot" procedure.
Authors: Andrew V Mossine; Sean S Tanzey; Allen F Brooks; Katarina J Makaravage; Naoko Ichiishi; Jason M Miller; Bradford D Henderson; Marc B Skaddan; Melanie S Sanford; Peter J H Scott Journal: Org Biomol Chem Date: 2019-09-19 Impact factor: 3.876
Authors: Xiaoyun Deng; Jian Rong; Lu Wang; Neil Vasdev; Lei Zhang; Lee Josephson; Steven H Liang Journal: Angew Chem Int Ed Engl Date: 2019-01-14 Impact factor: 15.336
Authors: Nickeisha A Stephenson; Jason P Holland; Alina Kassenbrock; Daniel L Yokell; Eli Livni; Steven H Liang; Neil Vasdev Journal: J Nucl Med Date: 2015-02-05 Impact factor: 10.057
Authors: Wei Chen; Hui Wang; Nicholas E S Tay; Vincent A Pistritto; Kang-Po Li; Tao Zhang; Zhanhong Wu; David A Nicewicz; Zibo Li Journal: Nat Chem Date: 2021-12-13 Impact factor: 24.274
Authors: Andrew V Mossine; Sean S Tanzey; Allen F Brooks; Katarina J Makaravage; Naoko Ichiishi; Jason M Miller; Bradford D Henderson; Thomas Erhard; Christian Bruetting; Marc B Skaddan; Melanie S Sanford; Peter J H Scott Journal: Nat Protoc Date: 2020-04-08 Impact factor: 13.491
Authors: So Jeong Lee; María T Morales-Colón; Allen F Brooks; Jay S Wright; Katarina J Makaravage; Peter J H Scott; Melanie S Sanford Journal: J Org Chem Date: 2021-09-10 Impact factor: 4.198
Authors: Valdemar L Andersen; Mikkel A Soerensen; Johan Hygum Dam; Niels Langkjaer; Henrik Petersen; Dirk Andreas Bender; Dan Fugloe; Tri Hien Viet Huynh Journal: EJNMMI Radiopharm Chem Date: 2021-06-12
Authors: Naoko Ichiishi; Allen F Brooks; Joseph J Topczewski; Melissa E Rodnick; Melanie S Sanford; Peter J H Scott Journal: Org Lett Date: 2014-06-03 Impact factor: 6.005